Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor

ÜNEK İ. T., ÇELTİK A., Yener S., YAVUZŞEN T., Alacacioglu A., Cokmert S., ...Daha Fazla

JOURNAL OF BUON, cilt.14, sa.1, ss.135-138, 2009 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 1
  • Basım Tarihi: 2009
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.135-138
  • Anahtar Kelimeler: hypoglycemia, neuroendocrine tumor, somatostatin analogues
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Somatostatin and its long-acting analogues are effective in symptom control in patients with functional neuroendocrine tumors; they are also able to control tumor growth. Somatostatin analogues are safe and generally well tolerated. In some cases they may cause serious complications. Somatostatin analogues are potent inhibitors of growth hormone (GH) and glucagon secretion. They cause impairment of hepatic glucose output and delay in intestinal absorption of carbohydrates. Patients with huge tumor mass and multiple liver metastases have increased risk of tumor-induced hypoglycemia. In these patients, long-acting octreotide may trigger serious hypoglycemia. The patients whose glucose control is dependent on counter-regulatory hormones should be monitored for the possibility of hypoglycemia. Herein, we present a patients with severe and prolonged hypoglycemia after long-acting octreotide treatment.